All Insights

Four widely held assets — VGT, VOO, VONG, and gold — moved in noticeably different directions over the same two-week window in July 2026, despite facing overlapping macro pressures. The divergence isn't random: it traces directly to how concentrated each fund's exposure is to the forces currently in play, from an AI-chip valuation reset to a shifting Fed rate outlook. This piece breaks down why sector concentration, not headline risk, is driving the split.

AI in pharma is often described as one trend. It's really two, and it only wins one on its own merits. In drug discovery, AI directly attacks the problem of finding the right molecule, letting small teams compete with giants using nothing but data and talent. In drug manufacturing, AI can't shortcut anything, since it depends on years of proprietary production data that only exists once a company has already built an expensive facility, for reasons that have nothing to do wit

From a chemically synthesized pill to a patient's own genetically engineered living cells, drug modalities span an enormous range of manufacturing difficulty. This article explains why the pharmaceutical industry needs so many different approaches in the first place, then ranks every major modality, from small molecules to gene therapy, by how hard it actually is to build, and why.

Antibody-drug conjugates are among the most complex drugs ever built, combining an antibody, a chemical linker, and a toxic payload into a single guided-missile therapy for cancer. That complexity hasn't stopped pharmaceutical giants from spending tens of billions of dollars chasing the technology. This article breaks down why ADCs are so hard to manufacture, why Japan's Daiichi Sankyo has built the strongest platform in the field, and how a newly approved bispecific ADC out

Seven real founders, seven different ways to fund an asset management firm. Here's what they have in common — and what each pathway actually requires of the person attempting it.

Ray Dalio started Bridgewater from his apartment with no sponsor, no anchor investor, and no reported founding capital. Here's how publishing his own reasoning became the entire trust mechanism.

Bobby Jain raised $5.3 billion to build an independent hedge fund from scratch. Two years later, he gave that independence back. Here's what the fastest, best-funded launch in this series reveals about what infrastructure actually costs.

Mohnish Pabrai had no Wall Street pedigree — just an IT consulting company he built and sold, and $1 million from eight friends and family members. Here's how that became a real asset management firm.

Fidelity has never taken outside capital, never gone public, and has stayed in the same family for four generations. Here's the acquisition that started it all, and what permanent control actually costs.

Two Lehman veterans started Blackstone with $400,000 of their own money and no leveraged buyout experience. Here's how advisory fees and one anchor investor got them to their first fund.